Thrivent Financial for Lutherans’s iBio IBIO Stock Holding History

Thrivent Financial for Lutherans’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-636	Closed	-$337K	–	2292
2020 Q1	$337K	Buy	+636	New	+$245K	﹤0.01%	1927

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Thrivent Financial for Lutherans's IBIO Position: Q2 2020 in Review

Thrivent Financial for Lutherans sold out of iBio (IBIO) in Q2 2020, closing a stake of 636 shares — an estimated $337K sold.

Thrivent Financial for Lutherans first reported a position in IBIO in Q1 2020 and held it in 1 quarter. The position peaked at $337K in Q1 2020. 57 funds tracked by Wall St. Rank hold IBIO as of Q2 2020.

Thrivent Financial for Lutherans reported no remaining iBio position as of Q2 2020 after selling out during the quarter.
Thrivent Financial for Lutherans sold 636 iBio shares in Q2 2020, an estimated $337K.
Thrivent Financial for Lutherans first reported a position in iBio in Q1 2020 and held it in 1 quarter.
Thrivent Financial for Lutherans's iBio position peaked at $337K in Q1 2020.
57 funds tracked by Wall St. Rank held iBio as of Q2 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2020, filed 12 Aug 2020.